FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

View source ↗

Summary

The FDA notes a supplemental application for Caprelsa (vandetanib) submitted by Genzyme Corporation, related to an update to its approved labeling/indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• Caprelsa (vandetanib)

Snippet

SUPPL AP for CAPRELSA (VANDETANIB)